BridgeBio price target raised to $42 from $37 at BMO Capital

finance.yahoo.com/news/bridgebio-price-target-raised-42-125021730.html

In This Article:
BMO Capital raised the firm’s price target on BridgeBio (BBIO) to $42 from $37 and keeps a Market Perform rating on the shares. The firm anticipates Attruby’s U.S. sales in Q2 to be $77M-$89M, reflecting 110%-145% sequential growth and 20%-40% revenues above consensus,…

This story appeared on finance.yahoo.com, 2025-06-05 12:50:21.
The Entire Business World on a Single Page. Free to Use →